169 related articles for article (PubMed ID: 31550719)
1. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
Reichardt P; Schlemmer M; Delgado Perez JR; Papai Z; Prausova J; Melichar B; Fumagalli E; Barone C; Bauer S; Pustowka A; Crippa S; Castellana R; Quiering C; Le Cesne A
Oncol Res Treat; 2019; 42(12):629-635. PubMed ID: 31550719
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Tolerability of 5-Year Adjuvant Imatinib Treatment for Patients With Resected Intermediate- or High-Risk Primary Gastrointestinal Stromal Tumor: The PERSIST-5 Clinical Trial.
Raut CP; Espat NJ; Maki RG; Araujo DM; Trent J; Williams TF; Purkayastha DD; DeMatteo RP
JAMA Oncol; 2018 Dec; 4(12):e184060. PubMed ID: 30383140
[TBL] [Abstract][Full Text] [Related]
3. Survival Outcomes Associated With 3 Years vs 1 Year of Adjuvant Imatinib for Patients With High-Risk Gastrointestinal Stromal Tumors: An Analysis of a Randomized Clinical Trial After 10-Year Follow-up.
Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hermes B; Schütte J; Cameron S; Hohenberger P; Jost PJ; Al-Batran SE; Lindner LH; Bauer S; Wardelmann E; Nilsson B; Kallio R; Jaakkola P; Junnila J; Alvegård T; Reichardt P
JAMA Oncol; 2020 Aug; 6(8):1241-1246. PubMed ID: 32469385
[TBL] [Abstract][Full Text] [Related]
4. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Joensuu H; Eriksson M; Sundby Hall K; Hartmann JT; Pink D; Schütte J; Ramadori G; Hohenberger P; Duyster J; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Sarlomo-Rikala M; Nilsson B; Sihto H; Monge OR; Bono P; Kallio R; Vehtari A; Leinonen M; Alvegård T; Reichardt P
JAMA; 2012 Mar; 307(12):1265-72. PubMed ID: 22453568
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant therapy with imatinib mesylate after resection of primary high-risk gastrointestinal stromal tumors in Japanese patients.
Kanda T; Nishida T; Wada N; Kobayashi O; Yamamoto M; Sawaki A; Boku N; Koseki M; Doi T; Toh Y; Kakeji Y; Sugiyama T; Komatsu Y; Kikuchi S; Ogoshi K; Katai H; Miyachi K; Hirota S; Ohtsu A
Int J Clin Oncol; 2013 Feb; 18(1):38-45. PubMed ID: 22105894
[TBL] [Abstract][Full Text] [Related]
6. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
Cohen MH; Johnson JR; Justice R; Pazdur R
Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
[TBL] [Abstract][Full Text] [Related]
7. Imatinib mesylate: in the treatment of gastrointestinal stromal tumours.
Croom KF; Perry CM
Drugs; 2003; 63(5):513-22; discussion 523-4. PubMed ID: 12600228
[TBL] [Abstract][Full Text] [Related]
8. Treatment outcomes in older patients with advanced gastrointestinal stromal tumor (GIST).
Rutkowski P; Bylina E; Lugowska I; Teterycz P; Klimczak A; Streb J; Czarnecka AM; Osuch C
J Geriatr Oncol; 2018 Sep; 9(5):520-525. PubMed ID: 29602734
[TBL] [Abstract][Full Text] [Related]
9. Quality of Surgery and Outcome in Localized Gastrointestinal Stromal Tumors Treated Within an International Intergroup Randomized Clinical Trial of Adjuvant Imatinib.
Gronchi A; Bonvalot S; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom HJ; van Coevorden F; Penel N; Kopp HG; Duffaud F; Goldstein D; Broto JM; Wardelmann E; Marréaud S; Smithers M; Le Cesne A; Zaffaroni F; Litière S; Blay JY; Casali PG
JAMA Surg; 2020 Jun; 155(6):e200397. PubMed ID: 32236507
[TBL] [Abstract][Full Text] [Related]
10. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
[TBL] [Abstract][Full Text] [Related]
11. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
Fu Y; Hao H; Guo L; Yang G; Zhang X
Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
[TBL] [Abstract][Full Text] [Related]
12. Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant: A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group, UNICANCER, French Sarcoma Group, Italian Sarcoma Group, and Spanish Group for Research on Sarcomas.
Casali PG; Le Cesne A; Poveda Velasco A; Kotasek D; Rutkowski P; Hohenberger P; Fumagalli E; Judson IR; Italiano A; Gelderblom H; Adenis A; Hartmann JT; Duffaud F; Goldstein D; Broto JM; Gronchi A; Dei Tos AP; Marréaud S; van der Graaf WT; Zalcberg JR; Litière S; Blay JY
J Clin Oncol; 2015 Dec; 33(36):4276-83. PubMed ID: 26573069
[TBL] [Abstract][Full Text] [Related]
13. Gastrointestinal stromal tumors (GIST): a single center experience.
Kostka R; Gürlich R; Koldová L
Acta Chir Belg; 2012 Jan; 112(1):33-9. PubMed ID: 22442907
[TBL] [Abstract][Full Text] [Related]
14. Adjuvant therapy of gastrointestinal stromal tumors.
Koshenkov VP; Rodgers SE
Curr Opin Oncol; 2012 Jul; 24(4):414-8. PubMed ID: 22572723
[TBL] [Abstract][Full Text] [Related]
15. Pazopanib plus best supportive care versus best supportive care alone in advanced gastrointestinal stromal tumours resistant to imatinib and sunitinib (PAZOGIST): a randomised, multicentre, open-label phase 2 trial.
Mir O; Cropet C; Toulmonde M; Cesne AL; Molimard M; Bompas E; Cassier P; Ray-Coquard I; Rios M; Adenis A; Italiano A; Bouché O; Chauzit E; Duffaud F; Bertucci F; Isambert N; Gautier J; Blay JY; Pérol D;
Lancet Oncol; 2016 May; 17(5):632-41. PubMed ID: 27068858
[TBL] [Abstract][Full Text] [Related]
16. Preoperative adjuvant therapy for locally advanced and recurrent/metastatic gastrointestinal stromal tumors: a retrospective study.
Qi J; Liu HL; Ren F; Liu S; Shi W; Liu WH; Cai GQ; Liao GQ
World J Surg Oncol; 2020 Apr; 18(1):70. PubMed ID: 32264886
[TBL] [Abstract][Full Text] [Related]
17. Opposing roles of KIT and ABL1 in the therapeutic response of gastrointestinal stromal tumor (GIST) cells to imatinib mesylate.
Rausch JL; Boichuk S; Ali AA; Patil SS; Liu L; Lee DM; Brown MF; Makielski KR; Liu Y; Taguchi T; Kuan SF; Duensing A
Oncotarget; 2017 Jan; 8(3):4471-4483. PubMed ID: 27965460
[TBL] [Abstract][Full Text] [Related]
18. Role of surgery in patients with focally progressive gastrointestinal stromal tumors resistant to imatinib.
Gao X; Xue A; Fang Y; Shu P; Ling J; Qin J; Hou Y; Shen K; Sun Y; Qin X
Sci Rep; 2016 Mar; 6():22840. PubMed ID: 26946961
[TBL] [Abstract][Full Text] [Related]
19. S0502: A SWOG Phase III Randomized Study of Imatinib, With or Without Bevacizumab, in Patients With Untreated Metastatic or Unresectable Gastrointestinal Stromal Tumors.
Blanke CD; Rankin C; Corless C; Eary JF; Mulder K; Okuno SH; George S; Heinrich M
Oncologist; 2015 Dec; 20(12):1353-4. PubMed ID: 26576593
[TBL] [Abstract][Full Text] [Related]
20. Long-term outcome of molecular subgroups of GIST patients treated with standard-dose imatinib in the BFR14 trial of the French Sarcoma Group.
Patrikidou A; Domont J; Chabaud S; Ray-Coquard I; Coindre JM; Bui-Nguyen B; Adenis A; Rios M; Bertucci F; Duffaud F; Chevreau C; Cupissol D; Pérol D; Emile JF; Blay JY; Le Cesne A;
Eur J Cancer; 2016 Jan; 52():173-80. PubMed ID: 26687836
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]